MORPHOSYS ANNOUNCES EXTENSION OF ANTIBODY COLLABORATION WITH BAYER

A A

MorphoSys AG (Frankfurt:MOR) (Prime Standard Segment, TecDAX) announced today the extension of its collaboration with Bayer Pharmaceuticals Corporation. The collaboration is extended by five years, with a termination option after the first collaboration year. Under the terms of the extended agreement, MorphoSys grants Bayer access to its proprietary HuCAL GOLD(r) antibody library for use in Bayer's drug discovery programs at its research site in West Haven, CT, U.S.A. Additionally, the two parties undertake to commence up to 25 new therapeutic antibody programs should the collaboration run its full course.

PrimeZone (http://www.primezone.com/newsroom/news.html?d=90933)